Lung Cancer Clinical Trials in New York

Showing 401-420 of 806 trials

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NCT05815186

Study record has been combined with NCT05815173. See NCT05815173 for summary.

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NYU Langone HealthStarted Apr 2024

Garden City, New York, United States • Mineola, New York, United States • New Hyde Park, New York, United States +3 more locations

COMPLETEDPhase 1/2< 1 mile

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more

NextCure, Inc.109 participantsStarted Oct 2018

Los Angeles, California, United States • New Haven, Connecticut, United States • Hackensack, New Jersey, United States +3 more locations

COMPLETEDPhase 1/2< 1 mile

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.

Small Cell Lung Cancer

Bristol-Myers Squibb106 participantsStarted Nov 2014

New York, New York, United States • Durham, North Carolina, United States • Winston-Salem, North Carolina, United States +13 more locations

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

BMS-986012 in Relapsed/Refractory SCLC

Lung Cancer Trials in Other Cities

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Prospective Clinicogenomic Program

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Risk Communication in African American Smokers

A Study of PRT2527 in Participants With Advanced Solid Tumors

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung EpiCheck Biomarkers Development Study

Survival Prolongation by Rationale Innovative Genomics

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Other Conditions in New York